Skip to main content

NEO

Stock

NEO

Stock
Health Care
Diagnostics & Research

Performance overview

NEO Price
Price Chart

Forward-looking statistics

Beta
1.14
Risk
68.38%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees2K
Market cap$1.7B

Fundamentals

Enterprise value$1.2B
Revenue$672.4M
Revenue per employee—
Profit margin-11.54%
Debt to equity68.08

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.61
Dividend per share—
Revenue per share$5.30
Avg trading volume (30 day)$14M
Avg trading volume (10 day)$14M
Put-call ratio—

Macro factor sensitivity

Growth+1.8
Credit+3.2
Liquidity-1.2
Inflation-1.9
Commodities+0.5
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio37.75
Price to sales1.45
P/E Ratio37.75
Enterprise Value to Revenue1.77
Price to book1.09

Upcoming events

Next earnings dayFebruary 18, 2025
Next dividend day—
Ex. dividend day—

News

NeoGenomics (NEO) Reports Break-Even Earnings for Q1

NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago.

Zacks Investment Research (April 29, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free